Analysts' Actions: Cisco, Office Depot, Pharmacyclics, Staples

NEW YORK (TheStreet) -- RATINGS CHANGES

Bonanza Creek (BCEI) was upgraded at Topeka Capital to buy from hold. Twelve-month price target is $68. Wattenberg acquisition should be highly accretive to earnings, Topeka Capital said.

Bio-Rad Laboratories (BIO) was downgraded to hold at TheStreet Ratings.

Cepheid (CPHD) was upgraded at Needham to buy from hold. Twelve-month price target is $50. More positive on the company, following meetings with management, Needham said.

Cisco (CSCO) was upgraded at Deutsche Bank to buy from hold. Twelve-month price target is $30. See stronger-than-anticipated business ramp, Deutsche Bank said.

CIT Group (CIT) was downgraded to sell at TheStreet Ratings.

Guidewire (GWRE) was upgraded at Citigroup to neutral. Twelve-month price target is $43. Expectations have come in and company fundamentals are improving, Citigroup said.

Office Depot (ODP) was upgraded at Goldman Sachs to buy from neutral. Twelve-month price target is $7. Company can likely exceed consensus earnings expectations, Goldman Sachs said.

Palo Alto (PANW) was upgraded at Nomura to buy from neutral. Twelve-month price target is $80. See fewer risks around the Juniper litigation, Nomura said.

Pharmacyclics (PCYC) was downgraded at RBC Capital to sector perform from outperform. Twelve-month price target is $95. Company is facing potential growth headwinds, RBC Capital said.

Staples (SPLS) was downgraded at Goldman Sachs to sell. Twelve-month price target is $11. Company is facing margin pressure, Goldman said.

If you liked this article you might like

Bet on Animal Health By Investing in Idexx Laboratories, Analysts Say

Cepheid (CPHD) Stock Downgraded to 'Neutral' at Baird

Cepheid (CPHD) Stock Price Target Raised at Barclays on Danaher Deal

Abbott's Alere Pushback Could Color Future Dealmaking Efforts

Jim Cramer's 'Mad Money' Recap: These Stocks Will Rise, Whatever the Fed Does